Experience of Tocilizumab in Hospital Patients with Moderate Covid-19
Bulletin of Russian State Medical University
; - (2):43-49, 2022.
Article
in English
| EMBASE | ID: covidwho-2228435
ABSTRACT
Severe form of COVID 19 has been linked to the phenomenon of dysregulated inflammation with excessive cytokine release and elevated interleukin 6 (IL6) levels. Suppressive agents enabling specific inhibition of cytokines, notably monoclonal antibodies to IL6 and its receptors, have been applied as a rescue therapy in COVID 19 despite the underexplored clinical scope for these biologic medications. This study aimed to evaluate the clinical utility of IL6 receptor antagonist tocilizumab in moderate symptomatic COVID 19 prone to aggravation. The retrospective cohort study enrolled two groups of hospitalized patients (a total of n = 72) diagnosed with moderate COVID-19. The main group received a single 400 mg dose of tocilizumab (TCZ) on top of standard therapy. The comparative analysis included statistical evaluation for a number of clinical and laboratory parameters at reference time points and disease outcomes with regard to treatment strategy. Overall, TCZ administration provided no advantages in terms of oxygen supplementation status, disease progression, or survival. Lethal cases constituted 19.2% (10 pts) and 5% (1 pt) in TCZ and comparison groups, respectively. The results indicate that administration of monoclonal antibody drugs in hospital patients with COVID-19 must follow differential schemes with regard to the disease severity and comorbidities, as well as proper commencement schedules. Copyright © 2022 Pirogov Russian National Research Medical University. All rights reserved.
acute respiratory distress syndrome (ARDS); covid-19; dexamethasone; interleukin 6 (IL6) inhibitors; SARS-CoV-2; tocilizumab; adult; adult respiratory distress syndrome; aged; article; clinical evaluation; cohort analysis; comorbidity; controlled study; coronavirus disease 2019/dt [Drug Therapy]; coronavirus disease 2019/th [Therapy]; disease exacerbation; disease severity; female; hospital patient; human; major clinical study; male; nonhuman; oxygen therapy; retrospective study; statistical analysis; dexamethasone/dt [Drug Therapy]; tocilizumab/dt [Drug Therapy]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Bulletin of Russian State Medical University
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS